Lung function before and after COVID-19 in young adults: A population-based study

Ida Mogensen, MD, PhD, a Jenny Hallberg, PhD, a,b Sophia Björkander, PhD, a Likun Du, PhD, c Fanglei Zuo, PhD, c Lennart Hammarström, MD, PhD, c Qiang Pan-Hammarström, MD, PhD, c Sandra Ekström, PhD, d,e Antonios Georgelis, PhD, d Lena Palmberg, MD, PhD, d Christer Janson, MD, PhD, f Anna Bergström, PhD, d Erik Melen, MD, PhD, a,b and Inger Kull, PhD, a,b on behalf of the BAMSE COVID-19 Study Group* Stockholm, Huddinge, and Uppsala, Sweden

Background: There is limited evidence on the long-term impact of mild-to-moderate coronavirus disease 2019 (COVID-19) on lung function among young adults.

Objectives: We aimed to assess whether COVID-19 has a negative impact on lung function in young adults and whether asthma, allergic sensitization, or use of inhaled corticosteroids (ICSs) modifies a potential association.

Methods: Participants from the population-based BAMSE (Barn, Allergi, Miljö, Stockholm, Epidemiologi) cohort with spirometry assessed before (2016-2019) and after onset of the COVID-19 pandemic (2020-2021) were included. Serum levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain-specific IgG, IgM, and/or IgA (determined with ELISA) defined seropositivity. Mean change in lung function (ie, change in FEV1, forced vital capacity [FVC], and FEV1/FVC ratio expressed as percent of predicted [pp]) from before to after onset of the pandemic were compared between the seronegative and seropositive participants. In seropositive participants, change in lung function was assessed in relation to allergic sensitization and self-reported ICS use.

Results: Of the 853 included participants, 29% (n = 243) were seropositive. There were no differences in change in lung function between the seronegative and seropositive participants (for mean change in FEV1 pp [SD], seropositivity = 0.87% [4.79%] and seronegativity = 1.03% [4.76%] [P = .66] for difference using a t test; FVC pp (SD), seropositivity = 1.34% (4.44%) and seronegativity = 1.29% (4.27%) [P = .87]; and for FEV1/FVC pp (SD), seropositivity = -0.25% (3.13%) and seronegativity = -0.13% (3.15%) [P = .61]). Similar results were observed among participants with asthma (n = 147 [17%]). Among seropositive participants, allergic sensitization or ICS use did not influence lung function.

Conclusion: We found no evidence of mild-to-moderate COVID-19 affecting lung function long term in a population-based cohort of young adults. Moreover, neither asthma nor allergic sensitization nor ICS use affected the results. (J Allergy Clin Immunol Global 2022;1:37-42.)

Key words: Asthma, COVID-19, Lung function

The coronavirus disease 19 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory disorder. The major effect on pulmonary function in the acute phase is a decreased diffusion capacity, and this is associated with severity of disease.1–4 In hospitalized patients with severe disease, restrictive lung function impairment has been described.3–5 A difficulty, however, in evaluating the impact of COVID-19 on lung function measured with spirometry is the wide variability in lung function between individuals; specifically, the lung function of an individual with a habitually higher than average lung function can decline significantly before reaching a pathologic value. Whether spirometric lung function is also affected to an extent not reaching a clinically pathologic value is of interest both at a population level (for future public health consequences) and on an individual level (for better assessment of individual risks and follow-up measures).
Although the abnormalities observed in the acute phase of severe COVID-19 are found to improve during the months after clearance of the infection, the extent of persistently affected lung function in a specific individual is unknown. The available follow-up studies are generally performed on clinic populations, where the patients have been in contact with a health care provider and have in most cases been hospitalized. However, post–COVID-19 symptoms have been reported to affect individuals independent of disease severity, and the degree to which lung function is affected by less severe disease is not known. The availability in our cohort of before– and after–COVID-19 spirometric data from the pre–COVID-19 examination to the second phase, which was conducted from October 2020 to June 2021, 1453 of the participants responding in the first phase were invited participate in the second phase, which was conducted a web-based questionnaire open from August to November 2020.20

Change in lung function from before to during the pandemic was calculated on an individual level as the lung function at the COVID-19 follow-up study divided by the lung function at the pre–COVID-19 examination subtracted from the lung function at the COVID-19 examination. Previous COVID-19 was defined as seropositivity against SARS-CoV-2 and based on the presence of an anti–receptor-binding domain IgG level higher than 25.09 arbitrary units (AU)/mL, IgM level higher than 14.42 AU/mL, and/or IgA level higher than 2.61 AU/mL. Antibodies in serum were measured on the same day as performance of the spirometric examination. Antibody levels were determined by ELISA, as previously described in detail.22,23 Cutoff values for antibody positivity were determined on the basis of receiver operating characteristic curves with data from historical (prepandemic) control samples and convalescent patients with COVID-19.24

Asthma was considered present if the participant fulfilled the following criteria: a doctor’s diagnosis of asthma (ever) and asthma symptoms and/or asthma medication use during the past year at either of the 2 examinations. Smoking was defined as present when a participant reported intermittent or daily use of cigarettes at the COVID-19 examination. Allergic sensitization was assessed at the pre–COVID-19 examination and defined as an IgE level against common airborne allergens (Phadiatop mix, Thermo Fischer Scientific, Uppsala, Sweden) of 0.35kU/L or higher. Use of an inhaled corticosteroid (ICS) was self-reported at the COVID-19 examination covering the period from 4 weeks before the first COVID-19-questionnaire until the clinical examination. Participants were divided into the categories no use and as-needed/ continuous use during this period.

Self-reported COVID-19 symptoms

The participants reported suspected symptoms of COVID-19 from onset of the pandemic to the time of the clinical examination. The group with antibodies against SARS-CoV-2 was divided into those with self-reported respiratory symptoms (cough or dyspnea) and those without such symptoms. The group was also divided in into those reporting being bedbound at least 1 day during a suspected COVID-19 disease period and those who were not bedbound.

Study design and statistical analyses

The change in lung function from the pre–COVID-19 examination to the COVID-19 examination had a normal distribution for all lung function parameters. The change was compared between the seropositive group and the seronegative group by using t tests and linear regressions and thereafter in a multiple regression model adjusted for sex, body mass index (BMI), smoking (daily or intermittent), time between the examinations, and lung function at the pre–COVID-19 examination. These parameters were chosen as confounders having a potential association with the risk of getting infected by SARS-CoV-2.25–27 and change in lung function.28–30 Further, to assess the impact of a presumably more recent infection, IgM-positive participants (regardless of seropositivity for other antibodies) were compared with the seronegative participants in a linear regression. Thereafter, the same analyses were done for the subgroup with asthma.

In the seropositive group, change in lung function was compared between the groups with and without allergic sensitization and the groups with and without self-reported ICS use. As sensitivity analyses, stratifications were done for sex, elevated BMI (>25 kg/m²), and smoking (all at the COVID-19 follow-up) to assess the effect modification by these variables. Comparisons between change in lung function among seropositive participants reporting respiratory symptoms or having been bedbound and seronegative participants were done. Further, a lung function comparison between seropositive and seronegative participants was insufficient blood samples, or vaccination against SARS-CoV-2, a total of 853 participants remained (Fig 1).

Lung function was measured (according to European Respiratory Society/American Thoracic Society guidelines11) by using a Vyaire Vntus spirometer (Vyaire Medical, Chicago, Ill) at both examinations to determine FEV₁, forced vital capacity (FVC), and the ratio FEV₁/FVC. Measured values were expressed as percent of predicted (pp) using the Global Lung Initiative reference material.22 The change between examinations was calculated on an individual level as the lung function at the pre–COVID-19 examination subtracted from the lung function at the COVID-19 examination.

Abbreviations used

- AU: Arbitrary unit
- BAMSE: Barn, Allergi, Miljö, Stockholm, Epidemiologi
- BMI: Body mass index
- COVID-19: Coronavirus disease 2019
- FVC: Forced vital capacity
- ICS: Inhaled corticosteroid
- pp: Percent of predicted
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
done with lung function measured in milliliters and as a ratio adjusted for height at the COVID-19 follow-up and sex.

A P value of .05 or less was considered statistically significant. Missing data were handled with complete cases. The statistical analyses were done with STATA statistical software, release 16.1 (StataCorp, College Station, Tex).

Ethical permission
The study was approved by the Swedish Ethical Review Authority (Dnr 2016/1380-31/2 and 2020-02922), and all participants provided written informed consent.

RESULTS
Characteristics in the pre–COVID-19 and COVID-19 examinations
Of the included population (N = 853), 17% (n = 147) fulfilled the criteria for asthma at 1 or both follow-ups. The mean period between the 2 examinations was 3.2 years (range 1.6-4.4 years). The prevalence of smoking decreased between the examinations. The mean FEV₁ and FVC expressed as pp increased (Table I). Compared with the whole cohort participating in the pre–COVID-19 examination, the study cohort had a lower prevalence of males (36% vs 44% [P < .001]) and a higher percentage of participants with a BMI of 25 or higher (20% vs 23% [P = .019]), but it did not differ from the standpoints of prevalence of current smokers, allergic sensitization, or lung function.

In total, 29% of the participants were seropositive (n = 243) and 71% were seronegative (n = 607) for SARS-CoV-2 antibodies. The majority of seropositive participants (81% [n = 196]) had SARS-CoV-2–specific IgG antibodies (Table I). Among those with positive serology, 149 (61%) reported respiratory symptoms (cough and/or dyspnea) and 121 (50%) reported being bedbound during the disease (with 22 of them [9%] reporting being bedbound for a week or more). Of the seropositive participants, 1 reported having been admitted to the hospital because of COVID-19. However, 36 participants (15%) reported no symptoms indicative of COVID-19. Hence, the majority of the participants had mild disease.

The prevalence of females was higher among the participants with asthma than among the participants without asthma (71% vs 62% [P = .031]). We found no significant differences in time between the examinations, prevalence of smoking, or BMI between participants with and without asthma (data not shown).

Comparisons of characteristics between seropositive and seronegative groups
There were no significant differences between the seropositive and seronegative groups from the standpoints of time between the examinations, asthma prevalence, prevalence of allergic sensitization, smoking, or lung function at the COVID-19 examination (Table II). The seropositive subjects with asthma also did not differ from the seronegative subjects with asthma (see Table E1 in the Online Repository at www.jaci-global.org).

Change in lung function between the pre–COVID-19 and COVID-19 examinations
The crude linear regression analysis comparing change in lung function in the seropositive and seronegative groups did not reveal any significant differences (Fig 2, A). The mean changes in lung function in the seronegative versus seropositive groups were as follows: for FEV₁ pp (SD), 0.87% (4.79%) for seropositive participants versus 1.03% (4.76%) for seronegative participants (P = .66 [t test]); for FVC pp (SD), 1.34% (4.44%) for seropositive participants versus 1.29% (4.27%) for seronegative participants (P = .87); and for FEV₁/FVC pp (SD), −0.25% (3.13%) for seropositive participants versus −0.13% (3.15%) for seronegative participants (P = .61) (for presentation of the values in full, see Table E2 in the Online Repository at www.jaci-global.org). Adjustment for a priori–identified confounders (sex, BMI, smoking, time between the examinations, and lung function at the pre–COVID-19 examination) did not affect the estimates (Fig 2, A).

When participants positive for SARS-CoV-2–specific IgM were compared with seronegative participants, similar results were found (Fig 2, A). Among the participants with asthma (n = 147), no significant differences in lung function estimates were found between the seropositive (n = 38) and seronegative groups (n = 109) in the linear regression model (Fig 2, B). The estimates in the seropositive group showed a nonsignificant tendency toward a more obstructive pattern with a smaller increase in FEV₁ (P = .24) and a decrease in FEV₁/FVC (P = .16) compared with in the
estimates in the seronegative group (see Table E2). This tendency remained similar after adjustments for sex, BMI, smoking (daily or intermittent use), time between examinations, and lung function at the pre–COVID-19 examination.

Both FEV₁ pp and FVC pp in those participants with asthma and IgM antibodies (n = 13) did increase less than in the seronegative asthma group (n = 109), although none of the comparisons were statistically significant (FEV₁ P = .13; FVC P = .37; and FEV₁/FVC P = .32) (Fig 2, B). There was no interaction between asthma and seropositivity from the standpoint of change in lung function (all P > .10).

### Allergic sensitization and ICS use in seropositive participants and change in lung function

In the analyses comparing change in lung function in seropositive participants with or without allergic sensitization or reported ICS use, the findings were no different between these exposures and change in lung function (Fig 3).

### Self-reported COVID-19 symptoms and lung function

No difference in lung function was found between the 62% (n = 149) of seropositive participants with reported respiratory symptoms and the seronegative participants, although there was a trend for a higher increase in FVC (P = .068) than in the seronegative group (see Table E4 in the Online Repository at www.jaci-global.org). Assessment of the change in lung function in the 50% (n = 121) of seropositive participants reporting being bedbound during presumed COVID-19 did not reveal any differences in change in lung function from that in seronegative participants (see Table E4).

### Sensitivity analyses

Stratification of the main analysis by sex, elevated BMI, or current smoking did not demonstrate any significant associations between seropositivity and change in lung function in these groups (see Table E3 in the Online Repository at www.jaci-
asthma exacerbations. In children, Tosca et al.31 did not find this has, however, not been found to be a prominent trigger for asthma exacerbations have in some cases been reported in association with COVID-19,32,33 although they are not seen on a regular basis. COVID-19 may influence lung function in young adults.

DISCUSSION

In the present study based on the well-characterized population-based BAMSE birth cohort, we did not find evidence for a COVID-19–associated impairment in lung function in young adults with or without asthma. No association between allergic sensitization or ICS use and change in lung function was found in seropositive participants.

In the small group with IgM antibodies among the participants with asthma, the results suggested a possible spirometric worsening in proximity to the infection, with a nonsignificant lower change in pp lung function than in the seronegative group with asthma. A possible explanation for this finding could be an exacerbation of the asthma in proximity to the infection. Level of IgM against SARS-CoV-2 is commonly measurable in the first month(s) after the onset of COVID-19, but it then slowly declines in most cases, becoming absent after 6 months.23 Viral respiratory infections, including those caused by coronaviruses, are common triggers for asthma exacerbations.36 COVID-19 has, however, not been found to be a prominent trigger for asthma exacerbations. In children, Tosca et al.31 did not find COVID-19 to affect lung function or asthma control. In adults, asthma exacerbations have in some cases been reported in association with COVID-19,2,23 although they are not seen on a population level.34 Our interpretation of the data would still be an effect on the asthma in proximity to the infection. This is also supported by the finding that the difference was reduced when analyzing the whole seropositive group with asthma (ie, when also including participants who had lost their IgM response). In addition to that, the potential differences found in our study are small and probably of limited clinical importance.

Presence of allergic sensitization was not found to affect the change in lung function in the seropositive group. Also, ICS use during the COVID-19 pandemic could not be linked to change in lung function. Earlier studies have found these factors to possibly protect against more severe COVID-19 disease.16,17 However, in our young cohort, most of the participants had mild disease, and a potential protective effect for less severe disease could be difficult to detect.

A major strength of our study is the unique availability of lung function measurements both recently before and after onset of the pandemic, with the potential to detect small changes in lung function among individuals with confirmed COVID-19 disease versus among nonaffected individuals. The majority of our participants had a mild disease,36 reflecting the manifestations of COVID-19 seen in a population-based sample of young individuals. This does not however rule out the possibility that severe COVID-19 may influence lung function in young adults.

A weakness of our study is the lack of information on total lung capacity, thus not permitting conclusions regarding restrictive lung function impairment, even though the normal spirometry findings imply a significant restrictive impairment to be unlikely. Further, we used seropositivity as a marker for previous COVID-19 infection, thus not catching individuals for whom antibody responses were low or absent. Moreover, a decline in antibody levels could have occurred among participants infected early in the pandemic, with the study period reaching more than a year after onset of the pandemic. A decline in antibody levels has been found in approximately 2% of individuals on days 15 to 90 days after infection and 15% at 1 year after infection in Swedish data37; other studies have found such a decline in 15% to 20% of infected individuals, albeit in populations older than ours.23,36 This would lead to a misclassification of some participants with a previous COVID-19 infection and potentially attenuate the results. A further limitation is the possibility of a nonresponse bias, although 50% of the invited population did participate in the clinical follow-up. However, the seropositivity rate is consistent with the official Swedish public health data, with a prevalence of 30% among those between 16 and 19 years of age and 18% among

FIG 2. A, Regression coefficients and 95% CIs for the change in the seropositive group/IgM-positive group versus that in the seronegative group (reference group). B, Asthma group. Regression coefficients and 95% CIs for the change in the seropositive group/IgM-positive group versus that in the seronegative group (reference group) among participants with asthma. *Adjustments have been done for sex, BMI, current smoking, time between the examinations, and lung function at the pre–COVID-19 examination.

FIG 3. Regression coefficients and 95% CIs for the change in the seropositive participants with allergic sensitization versus that in participants without allergic sensitization (reference group), as well as for the seropositive participants with reported ICS use versus the participants without reported ICS use (reference group).
those between 20 and 64 years in the unvaccinated population in late April to early May 2021. A limitation for interpretation when having nonsignificant findings is the risk of a statistical-type error (ie, a sample size too small to detect significant differences). This could be the case in our study, especially in the group with asthma, which consisted of 146 individuals, 38 of whom were seropositive. However, the difference between the change in the seropositive asthma group and the change in the seronegative asthma group was small—less than 2% (Fig 2, B). Hence, a difference undetected because of small sample size is of unclear significance.

In conclusion, we found no evidence that COVID-19 results in impaired spirometric lung function in a population-based sample of young, healthy adults with mild-to-moderate disease. Further, we did not find any evidence indicating that participants with asthma are more susceptible to long-term lung function impairment. Allergic sensitization or recent ICS use did not significantly affect lung function among seropositive participants.

We thank the participants and their families participating in the BAMSE cohort and all staff involved in the study through the years.

Clinical implications: The finding that COVID-19 in young adults with a mainly mild case of disease does not affect spirometric lung function is reassuring for patients, health care providers, and public health management.

REFERENCES

1. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55:2001217.
2. Thomas M, Price OJ, Hull JH. Pulmonary function and COVID-19. Curr Opin Physiol 2021;21:29-35.
3. Frija-Masson J, Debay MP, Gilbert M, Lescure FX, Truffert F, Borie R, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J 2020;56:2001754.
4. Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respirology 2020;25:1-7.
5. Fumagalli A, Misuraca C, Bianchi A, Borsa N, Limonta S, Maggiolini S, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. Infection 2021;49:153-7.
6. Lv D, Chen X, Wang X, Mao L, Sun J, Wu G, et al. Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study. Ann Palliat Med 2020;9:3447-52.
7. Torres-Castro R, Vasconcellos-Castillo L, Alisna-Restoy X, Solís-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology 2021;27:328-37.
8. Li X, Wang C, Kon S, Luo P, Zhao M, Yu K. Lung ventilation function characteristics of survivors from severe COVID-19: a prospective study. Crit Care 2020;24:300.
9. Ekström S, Mogensen I, Georgelis A, Westman M, Almqvist C, Melén E, et al. General stress among young adults with asthma during the COVID-19 pandemic. J Allergy Clin Immunol 2022;149:105-15.
10. Amsterdam VA, Alarcon J, Pahor M, Lundell L, Fagerberg A, et al. Multicenter randomized placebo-controlled trial evaluating the effects of ashwagandha on quality of life in sarcopenic older adults: the SALVA study. J Gerontol A Biol Sci Med Sci 2020;75:1798-807.
11. van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Assessment of chronic bronchitis and risk factors in young adults: Results from BAMSE. Eur Respir J 2021;57:2002210.
12. Ekström S, Andersson N, Löqvist A, Lauber A, Georgelis A, Kull I, et al. COVID-19 among young adults in Sweden: self-reported long-term symptoms and associated factors. Scand J Pub Health 2022:58-93.
13. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society Technical statement. Am J Respir Crit Care Med 2019;200:70-88.
14. Quanjer PH, Stanojlovic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-33.
15. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrèll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) 2021;2:281:95.e4.
16. Björkjander S, Du L, Zao F, Ekström S, Wang Y, Wan H, et al. SARS-CoV-2 specific B- and T-cell immunity in a population-based study of young Swedish adults. J Allergy Clin Immunol 2021;149:65-75.e8.
17. Hohmann C, Pinart M, Tischer C, Gehring U, Heinrich J, Kull I, et al. The development of the MeDALL core questionnaires for a harmonized follow-up assessment of eleven European birth cohorts on asthma and allergies. Int Arch Allergy Immunol 2014;163:215-24.
18. de Luisgian S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis 2020;20:1034-42.
19. Pijls BG, Jolani S, Athereley A, Derckx RT, Dijkstra JR, Fransen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open 2021;11:e044640.
20. Wang X, Mensinga TT, Schouten JP, Rijcken B, Weiss ST. Determinants of maximal attained level of pulmonary function. Scand J Pub Health 2004;169:941-9.
21. Forno E, Han YY, Mullin J, Ciprandi G. Unaffected asthma control in children with mild asthma after COVID-19. Pediatr Pulmonol 2021;56:3068-70.
22. Ono Y, Oabayashi S, Horio Y, Niimi K, Hayama N, Hiro Y, et al. Asthma exacerbation associated with COVID-19 pneumonia. Allergol Int 2021;70:129-30.
23. Codispoti CD, Bandi S, Patel P, Mahdvania M. Clinical course of asthma in 4 cases of coronavirus disease 2019 infection. Ann Allergy Asthma Immunol 2020;125:208-10.
24. Garcia-Pachon E, Ruiz-Alcaraz S, Baaza-Martinez C, Zamora-Molina L, Soler-Sempere MJ, Padilla-Navas I, et al. Symptoms in patients with asthma infected by SARS-CoV-2. Respir Med 2021;185:106495.
25. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020;383:1757-66.
26. Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021;9:763-72.
27. Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol 2020;146:790-8.
28. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. Pediatr Allergy Immunol 2002;13(suppl 15):11-3.
29. Wang G, Hallberg J, Um Bergström P, Janson C, Pershagen G, Gruziova E, et al. Assessment of chronic bronchitis and risk factors in young adults: Results from BAMSE. Eur Respir J 2021;57:2002210.
30. Townsend L, Dowds J, O’Brien K, Sheill G, Dyer AH, O’Kelly B, et al. Persistent asthma are more susceptible to long-term lung function impairment. Allergic sensitization or recent ICS use did not significantly affect lung function among seropositive participants.